Takuro Miyazaki1, Takahiro Oto2, Meinoshin Okumura3, Hiroshi Date4, Takeshi Shiraishi5, Yoshinori Okada6, Masayuki Chida7, Takashi Kondo8, Takeshi Nagayasu9. 1. Department of Surgical Oncology, Nagasaki University Graduate School of Biomedical Sciences, 1-7-1 Sakamoto, Nagasaki, 852-8501, Japan. miyataku@nagasaki-u.ac.jp. 2. Department of Organ Transplant Center, Okayama University Graduate School of Medicine, Okayama, Japan. 3. Department of General Thoracic Surgery, Osaka University, Suita, Japan. 4. Department of Thoracic Surgery, Kyoto University, Kyoto, Japan. 5. Department of General Thoracic, Breast, and Pediatric Surgery, Fukuoka University, Fukuoka, Japan. 6. Department of Thoracic Surgery, Tohoku University, Sendai, Japan. 7. Department of Thoracic Surgery, Dokkyo Medical University, Mibu, Japan. 8. Tohoku Pharmaceutical University Hospital, Sendai, Japan. 9. Department of Surgical Oncology, Nagasaki University Graduate School of Biomedical Sciences, 1-7-1 Sakamoto, Nagasaki, 852-8501, Japan.
Abstract
OBJECTIVE: Lung transplant recipients have an increased de novo cancer risk due to long-term immunosuppression and several oncogenic viral infections. In Japan, to date, there have been no national surveys of the incidence of de novo malignancy after lung transplantation. METHODS: This national survey was conducted by the Japanese Society for Transplantation. The questionnaire was distributed to lung transplant institutions, asking about several clinical factors related to de novo malignancy patients transplanted from 2001 to 2010. RESULTS: 179 cases of lung transplantation were performed by seven institutions in Japan between 2001 and 2010. De novo malignancies occurred in 18 patients (10.1 %). The most common malignancy was a lymphoproliferative malignancy (12 cases, including 1 double de novo cancer after tongue cancer), followed by cervical cancer (4 cases), breast cancer (2 cases), and tongue cancer (1 case). The mean time of occurrence after transplantation was 37.8 (range 4-148) months. Reduction and/or withdrawal of immunosuppression for the treatment of malignancy was seen in 14 cases. Death due to cancer occurred in 6 cases. The overall 5-year survival of 18 patients was 58.9 %. The 5-year survival of post-transplant lymphoproliferative disorder was not significantly different from that of other malignancies (47.6 and 62.5 %, respectively; p = 0.33). CONCLUSIONS: This is the first national survey of the incidence of de novo malignancy after lung transplantation in Japan. The incidence was 10.1 % and post-transplant lymphoproliferative disorder was the most common malignancy.
OBJECTIVE: Lung transplant recipients have an increased de novo cancer risk due to long-term immunosuppression and several oncogenic viral infections. In Japan, to date, there have been no national surveys of the incidence of de novo malignancy after lung transplantation. METHODS: This national survey was conducted by the Japanese Society for Transplantation. The questionnaire was distributed to lung transplant institutions, asking about several clinical factors related to de novo malignancypatients transplanted from 2001 to 2010. RESULTS: 179 cases of lung transplantation were performed by seven institutions in Japan between 2001 and 2010. De novo malignancies occurred in 18 patients (10.1 %). The most common malignancy was a lymphoproliferative malignancy (12 cases, including 1 double de novo cancer after tongue cancer), followed by cervical cancer (4 cases), breast cancer (2 cases), and tongue cancer (1 case). The mean time of occurrence after transplantation was 37.8 (range 4-148) months. Reduction and/or withdrawal of immunosuppression for the treatment of malignancy was seen in 14 cases. Death due to cancer occurred in 6 cases. The overall 5-year survival of 18 patients was 58.9 %. The 5-year survival of post-transplant lymphoproliferative disorder was not significantly different from that of other malignancies (47.6 and 62.5 %, respectively; p = 0.33). CONCLUSIONS: This is the first national survey of the incidence of de novo malignancy after lung transplantation in Japan. The incidence was 10.1 % and post-transplant lymphoproliferative disorder was the most common malignancy.
Entities:
Keywords:
De novo malignancy; Immunosuppression; Lung transplantation
Authors: Roger D Yusen; Leah B Edwards; Anna Y Kucheryavaya; Christian Benden; Anne I Dipchand; Samuel B Goldfarb; Bronwyn J Levvey; Lars H Lund; Bruno Meiser; Joseph W Rossano; Josef Stehlik Journal: J Heart Lung Transplant Date: 2015-09-03 Impact factor: 10.247
Authors: Brandon E Kremer; Ran Reshef; Jamal G Misleh; Jason D Christie; Vivek N Ahya; Nancy P Blumenthal; Robert M Kotloff; Denis Hadjiliadis; Edward A Stadtmauer; Stephen J Schuster; Donald E Tsai Journal: J Heart Lung Transplant Date: 2011-11-23 Impact factor: 10.247
Authors: Josep M Campistol; Valentín Cuervas-Mons; Nicolás Manito; Luis Almenar; Manuel Arias; Fernando Casafont; Domingo Del Castillo; María G Crespo-Leiro; Juan F Delgado; J Ignacio Herrero; Paloma Jara; José M Morales; Mercedes Navarro; Federico Oppenheimer; Martín Prieto; Luis A Pulpón; Antoni Rimola; Antonio Román; Daniel Serón; Piedad Ussetti Journal: Transplant Rev (Orlando) Date: 2012-08-15 Impact factor: 3.943
Authors: Sergio A Acuna; Kimberly A Fernandes; Corinne Daly; Lisa K Hicks; Rinku Sutradhar; S Joseph Kim; Nancy N Baxter Journal: JAMA Oncol Date: 2016-04 Impact factor: 31.777
Authors: M Anile; F Venuta; D Diso; T De Giacomo; E A Rendina; M Rolla; F Ruberto; V Liparulo; M T Aratari; M Di Stasio; C Ricella; D Vitolo; F Longo; G F Coloni Journal: Transplant Proc Date: 2007 Jul-Aug Impact factor: 1.066
Authors: Sabine Roithmaier; Andrew M Haydon; Sherene Loi; Don Esmore; Ann Griffiths; Peter Bergin; Trevor J Williams; Max A Schwarz Journal: J Heart Lung Transplant Date: 2007-08 Impact factor: 10.247
Authors: Eric A Engels; Ruth M Pfeiffer; Joseph F Fraumeni; Bertram L Kasiske; Ajay K Israni; Jon J Snyder; Robert A Wolfe; Nathan P Goodrich; A Rana Bayakly; Christina A Clarke; Glenn Copeland; Jack L Finch; Mary Lou Fleissner; Marc T Goodman; Amy Kahn; Lori Koch; Charles F Lynch; Margaret M Madeleine; Karen Pawlish; Chandrika Rao; Melanie A Williams; David Castenson; Michael Curry; Ruth Parsons; Gregory Fant; Monica Lin Journal: JAMA Date: 2011-11-02 Impact factor: 157.335